FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386537724> ?p ?o ?g. }

• W4386537724 endingPage "ii76" @default.
• W4386537724 startingPage "ii75" @default.
• W4386537724 abstract "Abstract BACKGROUND Neurofibromatosis type 2-related schwannomatosis (NF2) is an autosomal dominant tumor-predisposition syndrome characterized by bilateral vestibular schwannomas (VS) as well as other nervous system tumors. Management decisions for NF2-related VS are typically predicated on tumor size, associated symptoms, patient age, and comorbidities. Observation, surgical resection, and stereotactic radiosurgery can be viable options. In patients with VS associated with NF2, vascular endothelial growth factor A (VEGF-A) inhibitor, bevacizumab, is a systemic treatment option. In this single institution study, we review our clinical experience in patients with NF2 who received bevacizumab for VS and evaluate the effect of bevacizumab treatment on VS growth and symptom progression. MATERIAL AND METHODS This is a retrospective analysis of patients seen at the Mayo Clinic Rochester Multidisciplinary NF2 Clinic. Three-dimensional volumetric data for VS were measured using manual segmentation with Visage PACS software under the direct supervision of a board-certified neuroradiologist. RESULTS Out of 76 patients with NF2 evaluated in the past 3 years, we identified 19 that received treatment with bevacizumab. Median age of NF2 diagnosis was 19 years (range 0.5-61) with a median NF2 phenotype severity score of 2 (range 1-3). Thirteen of these patients have discontinued bevacizumab, accounting for a median duration of 12.2 months (range 3.3-88 months) of bevacizumab treatment. Bevacizumab was discontinued due to hypertension (n=5), proteinuria and renal dysfunction (n=3), tumor progression (n=2), fatigue or other intolerance (n=2), or non-compliance (n=1). The remaining 6 patients are currently receiving bevacizumab treatment for a median duration of 9.4 months as of March 2023 (range 3.7-48.3 months). Fifteen patients had brain MRI data available to evaluate VS change during bevacizumab treatment, with partial response observed in 5 patients, stable disease in 8, and progression in 2. Ten of the 13 patients who stopped bevacizumab had MRI data to evaluate VS change following treatment termination. Within 6 months of bevacizumab discontinuation, 6 patients had rebound growth of their VS between 21-95% from their previous tumor volume, while 4 did not. Three patients with rebound growth went on to have surgery or irradiation for VS management. CONCLUSION Our single institution experience confirms that bevacizumab can slow progression of VS and symptoms associated with VS growth. However, we note that there is the potential for rapid VS growth following bevacizumab discontinuation, for which we propose heightened surveillance imaging and symptom monitoring for at least 6 months upon stopping anti-VEGF therapy." @default.
• W4386537724 created "2023-09-09" @default.
• W4386537724 creator A5004157649 @default.
• W4386537724 creator A5006728583 @default.
• W4386537724 creator A5007147060 @default.
• W4386537724 creator A5009702464 @default.
• W4386537724 creator A5013859670 @default.
• W4386537724 creator A5025687850 @default.
• W4386537724 creator A5029393006 @default.
• W4386537724 creator A5031473630 @default.
• W4386537724 creator A5035529864 @default.
• W4386537724 creator A5038906046 @default.
• W4386537724 creator A5039932404 @default.
• W4386537724 creator A5040089494 @default.
• W4386537724 creator A5048951491 @default.
• W4386537724 creator A5065657451 @default.
• W4386537724 creator A5077862692 @default.
• W4386537724 creator A5078064665 @default.
• W4386537724 creator A5086392575 @default.
• W4386537724 creator A5087866752 @default.
• W4386537724 date "2023-09-01" @default.
• W4386537724 modified "2023-10-16" @default.
• W4386537724 title "P11.16.B THE MAYO CLINIC MULTIDISCIPLINARY NF2 CLINIC EXPERIENCE OF BEVACIZUMAB IN NEUROFIBROMATOSIS TYPE 2-RELATED SCHWANNOMATOSIS PATIENTS WITH VESTIBULAR SCHWANNOMAS" @default.
• W4386537724 doi "https://doi.org/10.1093/neuonc/noad137.250" @default.
• W4386537724 hasPublicationYear "2023" @default.
• W4386537724 type Work @default.
• W4386537724 citedByCount "0" @default.
• W4386537724 crossrefType "journal-article" @default.
• W4386537724 hasAuthorship W4386537724A5004157649 @default.
• W4386537724 hasAuthorship W4386537724A5006728583 @default.
• W4386537724 hasAuthorship W4386537724A5007147060 @default.
• W4386537724 hasAuthorship W4386537724A5009702464 @default.
• W4386537724 hasAuthorship W4386537724A5013859670 @default.
• W4386537724 hasAuthorship W4386537724A5025687850 @default.
• W4386537724 hasAuthorship W4386537724A5029393006 @default.
• W4386537724 hasAuthorship W4386537724A5031473630 @default.
• W4386537724 hasAuthorship W4386537724A5035529864 @default.
• W4386537724 hasAuthorship W4386537724A5038906046 @default.
• W4386537724 hasAuthorship W4386537724A5039932404 @default.
• W4386537724 hasAuthorship W4386537724A5040089494 @default.
• W4386537724 hasAuthorship W4386537724A5048951491 @default.
• W4386537724 hasAuthorship W4386537724A5065657451 @default.
• W4386537724 hasAuthorship W4386537724A5077862692 @default.
• W4386537724 hasAuthorship W4386537724A5078064665 @default.
• W4386537724 hasAuthorship W4386537724A5086392575 @default.
• W4386537724 hasAuthorship W4386537724A5087866752 @default.
• W4386537724 hasConcept C126322002 @default.
• W4386537724 hasConcept C126838900 @default.
• W4386537724 hasConcept C141071460 @default.
• W4386537724 hasConcept C143998085 @default.
• W4386537724 hasConcept C2776694085 @default.
• W4386537724 hasConcept C2777802072 @default.
• W4386537724 hasConcept C2778679214 @default.
• W4386537724 hasConcept C2778984943 @default.
• W4386537724 hasConcept C2780387249 @default.
• W4386537724 hasConcept C2781447767 @default.
• W4386537724 hasConcept C509974204 @default.
• W4386537724 hasConcept C71924100 @default.
• W4386537724 hasConceptScore W4386537724C126322002 @default.
• W4386537724 hasConceptScore W4386537724C126838900 @default.
• W4386537724 hasConceptScore W4386537724C141071460 @default.
• W4386537724 hasConceptScore W4386537724C143998085 @default.
• W4386537724 hasConceptScore W4386537724C2776694085 @default.
• W4386537724 hasConceptScore W4386537724C2777802072 @default.
• W4386537724 hasConceptScore W4386537724C2778679214 @default.
• W4386537724 hasConceptScore W4386537724C2778984943 @default.
• W4386537724 hasConceptScore W4386537724C2780387249 @default.
• W4386537724 hasConceptScore W4386537724C2781447767 @default.
• W4386537724 hasConceptScore W4386537724C509974204 @default.
• W4386537724 hasConceptScore W4386537724C71924100 @default.
• W4386537724 hasIssue "Supplement_2" @default.
• W4386537724 hasLocation W43865377241 @default.
• W4386537724 hasOpenAccess W4386537724 @default.
• W4386537724 hasPrimaryLocation W43865377241 @default.
• W4386537724 hasRelatedWork W170878511 @default.
• W4386537724 hasRelatedWork W1963981444 @default.
• W4386537724 hasRelatedWork W1978439727 @default.
• W4386537724 hasRelatedWork W1979205039 @default.
• W4386537724 hasRelatedWork W2002835684 @default.
• W4386537724 hasRelatedWork W2007938786 @default.
• W4386537724 hasRelatedWork W2150481655 @default.
• W4386537724 hasRelatedWork W2313478524 @default.
• W4386537724 hasRelatedWork W2898718478 @default.
• W4386537724 hasRelatedWork W3212946080 @default.
• W4386537724 hasVolume "25" @default.
• W4386537724 isParatext "false" @default.
• W4386537724 isRetracted "false" @default.
• W4386537724 workType "article" @default.